All Articles

One year into its 2030 strategy, Domtar's new report reveals major gains in sustainability, from improved CDP scores to a historic land deal with an Indigenous Nation.

A novel membrane technology promises to speed up production of next-gen medicines by solving a critical, energy-intensive bottleneck in pharmaceutical manufacturing.

A new federal initiative taps in-home support leader Papa, signaling a major policy shift to integrate companionship and respite into formal dementia care.

An independent safety board just gave Medera's novel gene therapy for a stubborn form of heart failure a major endorsement, de-risking its path to the FDA.

As Toronto builds a massive waterfront community, a new library is its social centerpiece. But does this model of public-private partnership deliver on its promise?

Triller's audacious acquisition of a SpaceX stake sends its stock soaring, but can this high-stakes bet on a space giant save a company plagued by financial woes?

A new deal in Israel signals a shift from noisy, ineffective warnings to precise, life-saving insights. Is this the future of personalized medication safety?

Manufacturing giant Cummins is overhauling its global travel for 60,000+ staff with Navan's AI, a move signaling a major shift for legacy industries.

As construction firm JFB Holdings pivots to AI combat, its partner XTEND lands major defense deals, revealing a potent growth model for the autonomous age.

The company once known for late-night snacks is pivoting hard, aiming to acquire a Taiwanese tech giant in a deal that could be worth over a billion dollars.

The chocolatier's dual openings signal growth, but a look at the books reveals a deeper story of strategic overhaul, franchisee faith, and a high-stakes pivot.

SUI Group's expanded loan to Bluefin isn't just a deal; it's a strategic maneuver to consolidate Sui's DeFi landscape and forge a new model for institutional investment.

The animal health leader faces scrutiny in its Q2 earnings call after a rocky first quarter. All eyes are on its strategy to balance market pressures with future-focused bets.

The firm's new API lets mainstream brokers offer crypto staking, turning a niche activity into a key tool for revenue and client retention.

By combining vast datasets with patient-driven advocacy, a new alliance offers hope for angiosarcoma patients and a new model for rare disease research.

Trintech's new AI agents automate tedious financial analysis, but the real story is its push for 'governed autonomy' in a high-stakes AI arms race.

Mint Inc. and YAS Digital Group are launching a joint venture to insure AI. Can their data-driven model unlock the next wave of automation in Asia?

NeuroSense's PrimeC shows intriguing biomarker activity against Alzheimer's, targeting multiple disease pathways. Is this the shift away from single-target drugs?

With a stunning 106% IRR and key operational wins, Anfield is moving beyond promises. Is this the moment a US uranium junior proves its mettle?

For America's 250th, a new AI lets you 'chat' with George Washington. Is this the future of education or a high-tech historical minefield?